Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Diabetes Therapy

Tirzepatide convinces with superior HbA1c and weight reduction

    • Cardiology
    • Endocrinology and Diabetology
    • Market & Medicine
    • Partner Content
    • RX
    • Studies
  • 2 minute read

The dual GLP-1/GIP receptor agonist tirzepatide is currently being evaluated in Phase III clinical trials. In adult type 2 diabetics at increased cardiovascular risk, tirzepatide resulted in superior HbA1c and body weight reductions compared with titrated insulin glargine.

URPASS-4 is an open-label global study comparing the safety and efficacy of three doses of tirzepatide (5 mg, 10 mg and 15 mg) with titrated insulin glargine in more than 2000 people with type 2 diabetes who are at increased cardiovascular risk and are being treated with one to three oral antihyperglycemic agents (metformin, a sulfonylurea, or an SGLT-2 inhibitor).

Study participants had a mean diabetes duration of 11.8 years, baseline HbA1c at 8.52%, and body weight at baseline of 90.3 kg. Over 85% of participants had a history of cardiovascular events. At the highest tirzepatide dose, 90.7% of participants achieved an HbA1c of less than 7% – the American Diabetes Association’s recommended target for diabetics – after 52 weeks, and 43.1% achieved an HbA1c of less than 5.7%. This corresponds to an HbA1c reduction of 2.58%. During the same period, an average body weight reduction of 11.7 kg (13.0%) was achieved.

In the insulin glargine group, insulin dose was titrated according to a treat-to-target algorithm, with the goal of maintaining fasting blood glucose below 100 mg/dl. The starting dose of insulin glargine was 10 units per day, and the mean dose of insulin glargine after 52 weeks was 43 units per day. In those treated with insulin glargine, a 1.44% reduction in HbA1c and an average weight loss of 1.9 kg were achieved after 52 weeks.

The overall safety profile of tirzepatide in this patient population was comparable to the glucagon-like peptide-1 (GLP-1) receptor agonist class. Gastrointestinal adverse events were the most commonly reported adverse events, usually occurring during the escalation phase and then decreasing over time.

 

Source: “Lilly’s tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial,” 05/20/2021.

 

 

CARDIOVASC 2021; 20(2): 33

Publikation
  • CARDIOVASC
Previous Article
  • Coronary heart disease

Non-invasive diagnostics for suspected cases

  • Cardiology
  • Market & Medicine
  • RX
View Post
Next Article
  • The Parkinson therapy in the very old

Age does not make it better

  • Congress Reports
  • Geriatrics
  • Neurology
  • Pharmacology and toxicology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
View Post
  • 12 min
  • Liver steatosis with metabolic dysfunction

New nomenclature for non-alcoholic fatty liver disease

    • CME continuing education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • RX
    • Studies
View Post
  • 14 min
  • IBDmatters - Advanced Therapeutic Treatments

Examinations and considerations before therapy

    • CME continuing education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Infectiology
    • RX
    • Studies
    • Training with partner
View Post
  • 5 min
  • Obesity in childhood and adolescence

Multifactorial disease with multiple implications

    • Congress Reports
    • General Internal Medicine
    • Nutrition
    • Pediatrics
    • Prevention and health care
    • RX
View Post
  • 9 min
  • Venous thromboembolism prevention

PCSK9 inhibitors: Current evidence, mechanisms and unanswered questions

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Prostate cancer

NeuroSAFE: New surgical technique preserves erectile function

    • Congress Reports
    • Oncology
    • RX
    • Studies
    • Surgery
    • Urology
View Post
  • 7 min
  • Study report

Scabies treatment: benzyl benzoate in direct comparison with permethrin

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • General Internal Medicine
    • Infectiology
    • RX
    • Studies
    • Tropical and travel medicine
View Post
  • 14 min
  • Innovative approaches in glioblastoma treatment

Synergistic combination therapies and the potential of phytotherapy and mycotherapy

    • RX
    • Education
    • Neurology
    • Oncology
    • Pharmaceutical medicine
    • Phytotherapy
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Medical and psychosocial perspectives
  • 2
    New nomenclature for non-alcoholic fatty liver disease
  • 3
    Examinations and considerations before therapy
  • 4
    Interplay between cancer and mental illness
  • 5
    Constant dripping – alcohol and cancer

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.